Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer
June 26, 2023 03:00 ET
|
Immodulon
Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer Richard Couch, formerly at Celgene,...
ADR Ratio Change
June 22, 2023 16:15 ET
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Appeal of Delisting Determination
June 20, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
Paclitaxel Injection Market to Grow at a CAGR of -3.4% from 2023 to 2031, reaching US$ 484.5 million: As per TMR Study
June 16, 2023 16:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 17, 2023 (GLOBE NEWSWIRE) -- The global paclitaxel injection market stood at US$ 811.0 million in 2022, and the global market is projected to reach US$...
Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer
June 05, 2023 07:00 ET
|
Immodulon
Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertiseAdding further oncology experience to Immodulon’s leadership team as...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
May 26, 2023 16:05 ET
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
May 24, 2023 08:40 ET
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Posting of Annual Report & Notice of AGM
May 22, 2023 16:15 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
May 18, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
May 15, 2023 08:45 ET
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...